Arbutus Biopharma Corp
NASDAQ:ABUS
Arbutus Biopharma Corp
NASDAQ:ABUS
Price:
2.69 USD
-1.47%
Market Closed
Updated:
May 2, 2024
Arbutus Biopharma Corp
Cash from Financing Activities
|
Arbutus Biopharma Corp
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
Cash from Financing Activities
$30.6m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Arbutus Biopharma Corp's Cash from Financing Activities?
Cash from Financing Activities
30.6m
USD
30.6m
USD
Based on the financial report for Dec 31, 2023, Arbutus Biopharma Corp's Cash from Financing Activities amounts to 30.6m USD.
What is Arbutus Biopharma Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-1%
-1%
Over the last year, the Cash from Financing Activities growth was -4%. The average annual Cash from Financing Activities growth rates for Arbutus Biopharma Corp have been -29% over the past three years , -11% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
